We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Therapy Prevents Seizures in Rat Model of Epilepsy

By Biotechdaily staff writers
Posted on 01 Dec 2006
Neurologists working with a rat model have used gene therapy to prevent the development of epileptic seizures after brain injury.

Investigators at the Children's Hospital of Philadelphia (PA, USA) employed an adeno-associated virus vector to insert the alpha-4 subunit gene (GABRA4) promoter into the brains of rats. More...
This gene therapy was intended to stimulate the production of GABAA receptor alpha-1 subunits in the hippocampal dentate gyrus region of the animals' brains. Previous studies had demonstrated reduced expression of GABR alpha-1 subunits and increased expression of alpha-4 subunits in dentate gyrus of epileptic rats compared with controls.

After successful acclimation of the transplanted gene, the rats were injected with pilocarpine, a drug that caused the animals to experience an epileptic seizure (status epilepticus or SE). Results published in the November 1, 2006, issue of the Journal of Neuroscience revealed that enhanced alpha-1 expression in the dentate gyrus resulted in a threefold increase in mean seizure-free time after SE and a 60% decrease in the number of rats developing epilepsy (recurrent spontaneous seizures) in the first four weeks after SE.

"We have shown that there is a window to intervene after a brain insult to reduce the risk that epilepsy will develop,” explained senior author Dr. Amy R. Brooks-Kayal, associate professor of pediatric neurology at the Children's Hospital of Philadelphia. "This provides a proof of concept that altering specific signaling pathways in nerve cells after a brain insult or injury could provide a scientific basis for treating patients to prevent epilepsy. This study lays the foundation for a potential drug therapy that might act on the same signaling pathways, to prevent epilepsy after a brain insult such as an episode of SE.”



Related Links:
Children's Hospital of Philadelphia

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: 123RF

UK Project Advances Blood-Based Dementia Testing Toward Routine Clinical Care

Dementia is the leading cause of death in the UK, accounting for almost one in eight deaths, with more than 72,000 people dying from dementia, including Alzheimer’s disease, in 2025. Despite this burden,... Read more

Microbiology

view channel
Image: Schematic overview of the CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The platform combines broad-range amplification using conserved regions of the 16S and 23S rRNA genes with species-specific CRISPR recognition. Fluorescence-coded CRISPR droplets are paired with sample droplets containing amplified products, enabling multiplexed target recognition and signal decoding (Image Credit: Yiwen Yang, Jingsong Xu, Dakang Xu)

Nanodroplet CRISPR Technology Supports Rapid, Multiplexed Mycobacterial Identification

Mycobacterial infections are difficult to diagnose because closely related species can have different clinical and therapeutic implications. Nontuberculous mycobacteria (NTM) are increasingly recognized... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: TruVerus is designed to deliver a broad menu of routine blood tests from a small blood sample on a single, automated benchtop platform (Photo courtesy of Truvian Health)

Collaboration Advances Automated Benchtop Platform for Routine Blood Testing

Routine blood testing is central to clinical decision-making, but access can vary across laboratory and healthcare settings. Broader use of automated benchtop platforms may help integrate testing more... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.